within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AB02_CollagenaseClostridiumHistolyticum;

model CollagenaseClostridiumHistolyticum
  extends Pharmacolibrary.Drugs.ATC.M.M09AB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>M09AB02</td></tr><td>route:</td><td>intralesional</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Collagenase clostridium histolyticum is an enzymatic drug preparation containing a mixture of two purified collagenases derived from Clostridium histolyticum. It is used for the enzymatic disruption of collagen and is approved for the treatment of Dupuytren's contracture and Peyronie's disease. The drug is administered locally to affected tissues to degrade excess collagen.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies describing standard parameters (e.g., clearance, volume of distribution, bioavailability) in humans. The drug is administered by local injection, and systemic exposure is expected to be minimal.</p><h4>References</h4><ol><li><p>Bhatia, AC, et al., &amp; Gelbard, MK (2020). Human Pharmacokinetics and Safety of Subcutaneous Collagenase Clostridium Histolyticum in Women. <i>Journal of drugs in dermatology : JDD</i> 19(9) 852–856. DOI:<a href=&quot;https://doi.org/10.36849/JDD.2020.10.36849/JDD.2020.5048&quot;>10.36849/JDD.2020.10.36849/JDD.2020.5048</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33026751/&quot;>https://pubmed.ncbi.nlm.nih.gov/33026751</a></p></li><li><p>Kaplan, FT (2011). Collagenase clostridium histolyticum injection for the treatment of Dupuytren&#x27;s contracture. <i>Drugs of today (Barcelona, Spain : 1998)</i> 47(9) 653–667. DOI:<a href=&quot;https://doi.org/10.1358/dot.2011.47.9.1656502&quot;>10.1358/dot.2011.47.9.1656502</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21971540/&quot;>https://pubmed.ncbi.nlm.nih.gov/21971540</a></p></li><li><p>Anaissie, J, et al., &amp; Yafi, FA (2015). Collagenase Clostridium histolyticum for the pharmacological management of Peyronie&#x27;s disease. <i>Drugs of today (Barcelona, Spain : 1998)</i> 51(8) 457–468. DOI:<a href=&quot;https://doi.org/10.1358/dot.2015.51.8.2375756&quot;>10.1358/dot.2015.51.8.2375756</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26380384/&quot;>https://pubmed.ncbi.nlm.nih.gov/26380384</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end CollagenaseClostridiumHistolyticum;
